MME AUDE ILGART-DUPONT

Rhumatologue

📍 CHARLEVILLE-MEZIERES (08)SalariéRPPS 10001745347

✨ Profil synthétique

IA · 21/05/2026

MME AUDE ILGART-DUPONT est une rhumatologue salariée à CHARLEVILLE-MEZIERES. Ses publications PubMed portent sur diverses pathologies et techniques en rhumatologie, notamment l'arthrite juvénile et l'utilisation de csDMARDs. Elle a également publié des travaux sur l'épidémiologie et les registres en rhumatologie, ainsi que sur l'utilisation de l'intelligence artificielle dans ce domaine.

Expertises présumées

Arthrite juvénile
csDMARDs
Épidémiologie en rhumatologie
Intelligence artificielle en rhumatologie
Biomarqueurs en rhumatologie
Auto-anticorps
Registres en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

DIRECTION DES SERVICES DEPARTEMENTAUX DE L'EDUCATION NATIONALE DES ARDENNES
INSPECTION ACADEMIQUE SCE DEP DE L EDUCATION NATIONALE 20 AV FRANCOIS MITTERRAND CS 90101, 08000 CHARLEVILLE-MEZIERES
Activité non soignante

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

Annals of the rheumatic diseases · 2023

📚 61 citations🎯 RCR 6.70Top 5% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial

JAMA · 2024

📚 18 citations🎯 RCR 4.07Top 11% NIH🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

ImportanceIn 2013, the Trial to Assess Chelation Therapy (TACT) reported that edetate disodium (EDTA)–based chelation significantly reduced cardiovascular disease (CVD) events by 18% in 1708 patients with a prior myocardial infarction (MI).ObjectiveTo replicate the finding of TACT in individuals with diabetes and previous MI.Design, Setting, and ParticipantsA 2 × 2 factorial, double-masked, placebo-controlled, multicenter trial at 88 sites in the US and Canada, involving participants who were 50 years or older, had diabetes, and had experienced an MI at least 6 weeks before recruitment compared the effect of EDTA-based chelation vs placebo infusions on CVD events and compared the effect of high doses of oral multivitamins and minerals with oral placebo. This article reports on the chelation vs placebo infusion comparisons.InterventionsEligible participants were randomly assigned to 40 weekly infusions of an EDTA-based chelation solution or matching placebo and to twice daily oral, high-dose multivitamin and mineral supplements or matching placebo for 60 months. This article addresses the chelation study.Main Outcomes and MeasuresThe primary end point was the composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. Median follow-up was 48 months. Primary comparisons were made from patients who received at least 1 assigned infusion.ResultsOf the 959 participants (median age, 67 years [IQR, 60-72 years]; 27% females; 78% White, 10% Black, and 20% Hispanic), 483 received at least 1 chelation infusion and 476 at least 1 placebo infusion. A primary end point event occurred in 172 participants (35.6%) in the chelation group and in 170 (35.7%) in the placebo group (adjusted hazard ratio [HR], 0.93; 95% CI, 0.76-1.16; P = .53). The 5-year primary event cumulative incidence rates were 45.8% for the chelation group and 46.5% for the placebo group. CV death, MI, or stroke events occurred in 89 participants (18.4%) in the chelation group and in 94 (19.7%) in the placebo group (adjusted HR, 0.89; 95% CI, 0.66-1.19). Death from any cause occurred in 84 participants (17.4%) in the chelation group and in 84 (17.6%) in the placebo group (adjusted HR, 0.96; 95% CI, 0.71-1.30). Chelation reduced median blood lead levels from 9.03 μg/L at baseline to 3.46 μg/L at infusion 40 (P &amp;lt; .001). Corresponding levels in the placebo group were 9.3 μg/L and 8.7 μg/L, respectively.Conclusions and RelevanceDespite effectively reducing blood lead levels, EDTA chelation was not effective in reducing cardiovascular events in stable patients with coronary artery disease who have diabetes and a history of MI.Trial RegistrationClinicalTrials.gov Identifier: NCT02733185

Temporal Trends in the Rate of Revision Total Knee Arthroplasty for Prosthetic Joint Infection

Arthroplasty today · 2024

📚 4 citations🎯 RCR 1.89🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME AUDE ILGART-DUPONT

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (21) — classées par pathologie

Transversal8

Case report / série2

csDMARDs2

Épidémiologie & registres2

IA en rhumatologie2

Arthrite juvénile1

Biomarqueurs / Auto-Ac1

Essai clinique1

Ostéoporose1

Qualité de vie / PROMs1

Vraie vie / RWE1

Partager cette fiche